Across the recent three months, 26 analysts have shared their insights on UnitedHealth Group (NYSE:UNH), expressing a variety of opinions spanning from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 2 | 19 | 4 | 1 | 0 |
| Last 30D | 0 | 3 | 0 | 0 | 0 |
| 1M Ago | 1 | 4 | 1 | 0 | 0 |
| 2M Ago | 0 | 4 | 1 | 0 | 0 |
| 3M Ago | 1 | 8 | 2 | 1 | 0 |
Insights from analysts' 12-month price targets are revealed, presenting an average target of $347.65, a high estimate of $440.00, and a low estimate of $198.00. Observing a 1.06% increase, the current average has risen from the previous average price target of $344.00.
Investigating Analyst Ratings: An Elaborate Study
The analysis of recent analyst actions sheds light on the perception of UnitedHealth Group by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Lisa Gill | JP Morgan | Raises | Overweight | $425.00 | $310.00 |
| Ann Hynes | Mizuho | Raises | Outperform | $430.00 | $300.00 |
| Andrew Mok | Barclays | Raises | Overweight | $386.00 | $352.00 |
| Kevin Fischbeck | B of A Securities | Raises | Neutral | $390.00 | $350.00 |
| Lance Wilkes | Bernstein | Raises | Outperform | $433.00 | $379.00 |
| Matthew Gillmor | Keybanc | Raises | Overweight | $400.00 | $350.00 |
| Stephen Baxter | Wells Fargo | Raises | Overweight | $400.00 | $267.00 |
| Ricky Goldwasser | Morgan Stanley | Raises | Overweight | $395.00 | $325.00 |
| David Macdonald | Truist Securities | Raises | Buy | $365.00 | $310.00 |
| Lance Wilkes | Bernstein | Raises | Outperform | $379.00 | $337.00 |
| Andrew Mok | Barclays | Raises | Overweight | $352.00 | $337.00 |
| Sarah James | Cantor Fitzgerald | Maintains | Overweight | $440.00 | $440.00 |
| Ricky Goldwasser | Morgan Stanley | Lowers | Overweight | $325.00 | $342.00 |
| Kevin Fischbeck | B of A Securities | Raises | Neutral | $325.00 | $290.00 |
| Ann Hynes | Mizuho | Lowers | Outperform | $300.00 | $350.00 |
| Lisa Gill | JP Morgan | Lowers | Overweight | $310.00 | $418.00 |
| Stephen Baxter | Wells Fargo | Lowers | Overweight | $267.00 | $306.00 |
| Michael Ha | Baird | Lowers | Underperform | $198.00 | $312.00 |
| Ben Hendrix | RBC Capital | Lowers | Outperform | $286.00 | $355.00 |
| Michael Wiederhorn | Oppenheimer | Lowers | Outperform | $325.00 | $400.00 |
| Matthew Gillmor | Keybanc | Lowers | Overweight | $350.00 | $400.00 |
| Jessica Tassan | Piper Sandler | Lowers | Overweight | $317.00 | $353.00 |
| Kevin Fischbeck | B of A Securities | Lowers | Neutral | $290.00 | $300.00 |
| Kevin Fischbeck | B of A Securities | Lowers | Neutral | $300.00 | $350.00 |
| Stephen Baxter | Wells Fargo | Lowers | Overweight | $306.00 | $351.00 |
| David Macdonald | Truist Securities | Lowers | Buy | $345.00 | $360.00 |
Key Insights:
- Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to UnitedHealth Group. This information offers a snapshot of how analysts perceive the current state of the company.
- Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of UnitedHealth Group compared to the broader market.
- Price Targets: Delving into movements, analysts provide estimates for the future value of UnitedHealth Group's stock. This analysis reveals shifts in analysts' expectations over time.
Capture valuable insights into UnitedHealth Group's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
Stay up to date on UnitedHealth Group analyst ratings.
Discovering UnitedHealth Group: A Closer Look
UnitedHealth Group is one of the largest private health insurers and provides medical benefits to about 51 million members globally, including 1 million outside the US as of December 2024. As a leader in employer-sponsored, self-directed, and government-backed insurance plans, UnitedHealth has obtained massive scale in medical insurance. Along with its insurance assets, UnitedHealth's Optum franchises help create a healthcare services colossus that spans everything from pharmaceutical benefits to providing outpatient care and analytics to both affiliated and third-party customers.
Financial Milestones: UnitedHealth Group's Journey
Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.
Revenue Growth: Over the 3M period, UnitedHealth Group showcased positive performance, achieving a revenue growth rate of 12.91% as of 30 June, 2025. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: UnitedHealth Group's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of 3.05%, the company may face hurdles in effective cost management.
Return on Equity (ROE): UnitedHealth Group's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of 3.59%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): UnitedHealth Group's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of 1.1%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 0.84, caution is advised due to increased financial risk.
Analyst Ratings: Simplified
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. Click here to stay ahead of the market.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
